advertisement

Topcon

Heegaard S 12

Showing records 1 to 12 | Display all abstracts from Heegaard S

106366 Topical eye medications causing allergic contact dermatitis
Ahlström MG
Contact Dermatitis 2023; 88: 294-299
106638 Bidirectional 5-year risks of diabetic retinopathy, glaucoma and/or ocular hypertension: Results from a national screening programme
Sperling S
Acta Ophthalmologica 2023; 101: 384-391
106366 Topical eye medications causing allergic contact dermatitis
Skov L
Contact Dermatitis 2023; 88: 294-299
106638 Bidirectional 5-year risks of diabetic retinopathy, glaucoma and/or ocular hypertension: Results from a national screening programme
Stokholm L
Acta Ophthalmologica 2023; 101: 384-391
106366 Topical eye medications causing allergic contact dermatitis
Heegaard S
Contact Dermatitis 2023; 88: 294-299
106638 Bidirectional 5-year risks of diabetic retinopathy, glaucoma and/or ocular hypertension: Results from a national screening programme
Thykjaer AS
Acta Ophthalmologica 2023; 101: 384-391
106366 Topical eye medications causing allergic contact dermatitis
Zachariae C
Contact Dermatitis 2023; 88: 294-299
106638 Bidirectional 5-year risks of diabetic retinopathy, glaucoma and/or ocular hypertension: Results from a national screening programme
Pedersen FN
Acta Ophthalmologica 2023; 101: 384-391
106366 Topical eye medications causing allergic contact dermatitis
Garvey LH
Contact Dermatitis 2023; 88: 294-299
106638 Bidirectional 5-year risks of diabetic retinopathy, glaucoma and/or ocular hypertension: Results from a national screening programme
Möller S; Laugesen CS
Acta Ophthalmologica 2023; 101: 384-391
106366 Topical eye medications causing allergic contact dermatitis
Johansen JD
Contact Dermatitis 2023; 88: 294-299
106638 Bidirectional 5-year risks of diabetic retinopathy, glaucoma and/or ocular hypertension: Results from a national screening programme
Andersen N; Andresen J; Bek T; la Cour M; Hajari J; Heegaard S; Højlund K; Kawasaki R; Kolko M; Schielke KC; Rubin KH; Vestergaard AH; Grauslund J
Acta Ophthalmologica 2023; 101: 384-391

Issue 23-3

Change Issue


advertisement

Oculus